RATIONALE: Children with allergic reactions often present to the emergency department for treatment. We hypothesized that different types of medical providers, Allergy/Immunology (AI) and Emergency Medicine (EM), would vary in their approaches to management of allergic reactions. METHODS: This was a cross-sectional survey study of EM and AI providers in the University of Colorado hospitals and Colorado Asthma and Allergy Society. The survey consisted of 6 case scenarios of allergic reactions, with 4 representing anaphylaxis that resolved by the time of discharge. Following the scenarios, participants were asked questions about preferred initial therapy, adjunctive therapies, monitoring, outpatient prescription medications, and discharge instructions provided. Survey derivation and validation was accomplished by a multidisciplinary team of experts using a modified Delphi process. 1 Asthma Center and Allergy Unit, Verona University Hospital, Verona, Italy, 2 Haematology Unit, Verona University Hospital, Verona, Italy. RATIONALE: Systemic mast cell activation diseases are clinically characterized by an enhanced release of mast cell mediators. METHODS: We report on the use of omalizumab at the dose of 300 mg every four weeks, in three patients: case 1, male with indolent systemic mastocytosis and normal tryptase; case 2, female (normal tryptase), and case 3, male (tryptase: 50 mcg/l), with non clonal mast cell activation syndrome. All of them were not responsive to treatment with antihistamines and mast cell membrane-stabilising compounds: case 1 and case 2 experienced anaphylactic reactions every month; case 3 experienced cutaneous and respiratory symptoms on a weekly base. RESULTS: In Case 1 omalizumab therapy, started 16 months ago, is currently ongoing. He still assumes anti H1 and H2, and montelukast. Since the omalizumab treatment start, no symptoms occurred. Case 2 was treated with omalizumab for 16 months. An optimal disease control was immediately obtained and maintained even in the absence of anti H1 and H2, stopped 6 months after. During the 6 months after omalizumab discontinuation, no anaphylactic reactions were recorded. Case 3 started omalizumab 6 months ago. He also assumes anti H1 and H2, and montelukast. Beside a complete clinical control, his tryptase decreased to 30 mcg/l six months after. No adverse reaction of any grade was detected during the treatment course. CONCLUSIONS: Omalizumab is a safe and effective treatment option in Systemic mast cell activation diseases resistant to traditional therapies. To the best of our knowledge this is the first report concerning non-clonal mast cell activation syndrome. Division of Allergy & Immunology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY. RATIONALE: There is little published data on the impact of anaphylaxis in the elderly. We hypothesize that anaphylaxis in elderly patients is underrecognized. This study elucidates the frequency of anaphylaxis diagnosis and the demographic characteristics of those diagnosed as such among elderly patients admitted to New York (NY) hospitals from 2000-2010. METHODS: A retrospective analysis of hospitalized patients aged > _65 years in NY from 2000-2010 was conducted using the Statewide Planning and Research Cooperative System (SPARCS), a data reporting system that collects patient characteristics, diagnoses, treatments and services for each hospitalization. Identification of cases was performed using anaphylaxis ICD-9 codes or an ICD-9-based diagnostic algorithm incorporating the National Institutes of Allergy and Infectious Disease (NIAID) diagnostic criteria, as published by Harduar-Morano et al (2010). Descriptive statistics, frequencies and proportions were calculated. RESULTS: 3,673 hospitalizations were identified and analyzed. Anaphylaxis ICD-9 codes identified 1,790 (48.7%) cases, the algorithm identified 1,701(46.3%), and 182 (5.0%) were identified by both. The hospitalization rates appeared to increase during this period. Females comprised 61.45% and whites comprised 69.83% of the sample. Distribution by age differed by ascertainment method (ICD-9 vs. Algorithm) -Early-old (age 65-74) 53.80% vs. 41.80%, Middle-old (age 75-84) 35.03% vs. 38.92%, Late-old (age > _85) 11.17% vs. 19.28%. CONCLUSIONS: Anaphylaxis occurred among the hospitalized elderly population of NY. The hospitalization rates increased during the study period. Relying on anaphylaxis ICD-9 codes alone missed about half of possible cases. The identification, and possibly, impact of anaphylaxis among the elderly may differ depending on gender, race, and age.
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